News

Two domains or portions of the protein NS1 combine to form tiny tubules where double-stranded RNA is hidden from the immune system, researchers say.

The partnership will strengthen ongoing collaboration for the co-development of software tools for next-generation sequencing data analysis.

Oncolytics presents the interim results of the trial investigating intravenous REOLYSIN® in patients with bone and soft tissue sarcomas metastatic to the lung.

TaqMan® gene expression arrays chosen as platform of choice to improve pre-clinical safety research.

The new protocol exploits the company’s know-how and capabilities in development and manufacture of iv dosage forms and their efficient integration into clinical studies.

Celera has entered into a research collaboration with Abbott to identify genetic markers for one of Abbott’s investigational compounds.

The new round of financing which will enable the company to expand the business with the development of new products and sales channels in the US market.

Researchers are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

Oncolytics will pursue a pivotal randomized trial using the combination of REOLYSIN® with paclitaxel/carboplatin in refractory patients with head and neck cancers.

DxS K-RAS test will assist US oncologists in studying patient response to cancer therapies in clinical trials.